Harrow is an ophthalmic-focused pharmaceutical company. Co. engages in the development, production, sale and distribution of prescription medications. Co. owns and operates ImprimisRx, the ophthalmology-focused pharmaceutical-compounding business, and its branded drugs are marketed under its Harrow name. In addition, Co. also has non-controlling equity positions in Surface Ophthalmics, Inc., which is focused on development and commercialization of therapeutics for ocular surface diseases; and Melt Pharmaceuticals, Inc., which is focused on the development and commercialization of proprietary non-intravenous, sedation and anesthesia therapeutics for human medical procedures. When considering the Harrow Inc stock dividend history, we have taken known splits into account, such that the HROW dividend history is presented on a split-adjusted ("apples to apples") basis. Harrow Inc dividend history is presented both in graphical/chart form, and as a HROW dividend history data table along the right-hand column.
|
HROW Stock Dividend HistoryThe HROW dividend history graphic shown above is presented after taking into consideration any known stock split occurrences, in order to present the most directly comparable HROW historical dividend comparison possible. Historical dividends, when charted graphically, can reveal the long-term variability and/or growth within the HROW dividend history record. Also see the HROW stock dividend history data table along the right-hand column below. |
|
|
Strong Buy (4.00 out of 4) 90th percentile
(ranked higher than approx. 90% of all stocks covered)
Analysts' Target Price: HROW Forecast Based on data provided by Zacks Investment Research via Quandl.com |